Literature DB >> 22524260

Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.

B W Rohrbach1, J R Stafford, R S W Clermont, S M Reed, H C Schott, F M Andrews.   

Abstract

BACKGROUND: Pituitary pars intermedia dysfunction (PPID) is common in older horses.
OBJECTIVES: To determine diagnosis frequency, prognostic factors, long-term survival, and owner satisfaction with treatment. ANIMALS: Medical records from horses diagnosed with PPID, 1993-2004.
METHODS: A retrospective cohort design with data collected from the Veterinary Medical Data Base (VMDB) and a cohort of 3 VTHs. Proportional accessions, annual incidence, and demographics were compared for all accessions. During the same period, a subset of medical records (n = 44) was extracted and owners (n = 34) contacted to obtain long-term follow-up information.
RESULTS: Diagnoses of PPID were reported for 217 horses that presented to VTHs and were reported to the VMDB. Proportional diagnosis increased from 0.25/1,000 in 1993 to 3.72/1,000 in 2002. For 44 horses included in the follow-up study, the most commons signs were hirsutism (84%) and laminitis (50%). Of 34 horse owners contacted, the average time from onset of signs to diagnosis was 180 days. Improvement in ≥ 1 signs, 2 months after diagnosis, was reported by 9/22 (41%) of horse owners. Clinical signs and clinicopathologic data were not associated with survival, and 50% of horses were alive 4.6 years after diagnosis. Cause of death among horses (15/20; 85%) was euthanasia, and 11/15 (73%) were euthanized because of conditions associated with PPID. Most horse owners (28/29; 97%) said they would treat a second horse for PPID. CONCLUSION AND CLINICAL IMPORTANCE: PPID was diagnosed with increasing frequency, and 50% of horses survived 4.5 years after diagnosis. Owners were satisfied with their horses' quality of life and would treat a second horse if diagnosed.
Copyright © 2012 by the American College of Veterinary Internal Medicine.

Entities:  

Mesh:

Year:  2012        PMID: 22524260     DOI: 10.1111/j.1939-1676.2012.00932.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  6 in total

1.  Equine pituitary pars intermedia dysfunction: An international survey of veterinarians' approach to diagnosis, management, and estimated prevalence.

Authors:  James L Carmalt; Cheryl L Waldner; Andrew L Allen
Journal:  Can J Vet Res       Date:  2017-10       Impact factor: 1.310

2.  Incidence and risk factors for recurrence of endocrinopathic laminitis in horses.

Authors:  Melody A de Laat; Dania B Reiche; Martin N Sillence; James M McGree
Journal:  J Vet Intern Med       Date:  2019-04-10       Impact factor: 3.333

3.  Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership.

Authors:  Rebecca C Tatum; Cathy M McGowan; Rachel S Dean; Joanne L Ireland
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

4.  Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses.

Authors:  Remona Horn; Allison J Stewart; Karen V Jackson; Elizabeth L Dryburgh; Carlos E Medina-Torres; François-René Bertin
Journal:  J Vet Intern Med       Date:  2020-12-24       Impact factor: 3.175

5.  Short-Term Effects of Temperature and Thyrotropin-Releasing Hormone Stimulation on Adrenocorticotropin Stability in Horses.

Authors:  Sophia L Hinrichsen; Ka Y Yuen; Elizabeth L Dryburgh; François-René Bertin; Allison J Stewart
Journal:  Animals (Basel)       Date:  2022-01-28       Impact factor: 2.752

6.  Evaluation of combined testing to simultaneously diagnose pituitary pars intermedia dysfunction and insulin dysregulation in horses.

Authors:  Remona Horn; François-René Bertin
Journal:  J Vet Intern Med       Date:  2019-09-09       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.